Everolimus, when combined with exemestane, adds toxicity with minimal benefit for women with breast cancer
Journal Articles
- Overview
- Research
- Identity
- Additional Document Info
- View All
Overview
status
publication date
- October 2014
has subject area
- 1112 Oncology and Carcinogenesis (FoR)
- Breast Neoplasms (MeSH)
- Drug-Related Side Effects and Adverse Reactions (MeSH)
- Female (MeSH)
- Humans (MeSH)
- Oncology & Carcinogenesis (Science Metrix)
- Sirolimus (MeSH)
published in
- Annals of Oncology Journal